Novel tumor vaccine gp96-Ig fusion heat shock protein in advanced non-small cell lung cancer (NSCLC) patients who have failed palliative chemotherapy and erlotinib

被引：0
|
作者：
Podack, E.
Raez, L. E.
Fisher, E.
Leibovitch, E.
Gomez, J. E.
Baldie, P.
Tolba, K. A.
Santos, E. S.
Walker, G.
机构：
[1] Univ Miami, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Miami, Sch Med, Miami, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18042
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE I TRIAL OF A FUSION HEAT SHOCK PROTEIN (GP96-IG) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WHO HAVE FAILED PALLIATIVE CHEMOTHERAPY AND ERLOTINIB
    Raez, L. E.
    Fisher, E.
    Leibovitch, E.
    Baldie, P.
    Gomez, J.
    Tolba, K.
    Walker, G.
    Santos, E.
    Podack, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 155 - 155
  • [2] Immunotherapy with Adenocarcinoma Cells Transfected with HLA A1 and gp96-Ig Heat Shock Protein in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Raez, Luis E.
    Fisher, Eva
    Gomez, Jorge
    Walker, Gail
    Baldie, Paulette
    Santos, Edgardo
    Podack, Eckard
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S382 - S382
  • [3] PHASE I CLINICAL TRIAL OF ADENOCARCINOMA CELLS TRANSFECTED WITH HLA A1 AND GP96-IG HEAT SHOCK PROTEIN IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Raez, Luis E.
    Fisher, Eva
    Walker, Gail
    Gomez, Jorge
    Baldie, Paulette
    Mendoza-Puccini, Maria C.
    Santos, Edgardo S.
    Podack, Eckard
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1289 - S1290
  • [4] PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED ERLOTINIB/GEFITINIB WHO FAILED PREVIOUS CHEMOTHERAPY
    Madolangan, Jamaluddin
    Andarini, Sita Laksmi
    Hudoyo, Achmad
    RESPIROLOGY, 2014, 19 : 165 - 165
  • [5] PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH SECOND LINE ERLOTINIB/GEFITINIB WHO FAILED TO PREVIOUS CHEMOTHERAPY
    Madolangan, Jamaluddin
    Hudoyo, Ahmad
    Andarini, Sita
    RESPIROLOGY, 2015, 20 : 101 - 101
  • [6] Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
    Neumair, P.
    Joos, L.
    Warschkow, R.
    Ess, S.
    Hitz, F.
    Frueh, M.
    Brutsche, M. H.
    Baty, F.
    Krahenbuhl, S.
    Jorger, M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S131 - S131
  • [7] Palliative Chemotherapy with Oral Metronomic Vinorelbine in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unsuitable for Chemotherapy
    Banna, Giuseppe
    Anile, Giuseppe
    Castaing, Marine
    Nicolosi, Maurizio
    Strano, Salvatore
    Marletta, Francesco
    Cali, Stefania
    Lal, Rohit
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S907 - S908
  • [8] Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
    Kim, Seung Tae
    Uhm, Ji Eun
    Lee, Jeeyun
    Sun, Jong-mu
    Sohn, Insuk
    Kim, Seon Woo
    Jung, Sin-Ho
    Park, Yeon Hee
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    LUNG CANCER, 2012, 75 (01) : 82 - 88
  • [9] Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
    Ahn, J.
    Kim, S.
    Ahn, M.
    Lee, J.
    Uhm, J.
    Sun, J.
    Park, K.
    Park, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Palliative chemotherapy (QT) and prognostic factors in elderly patients with advanced non-small Cell lung cancer (NSCLC)
    Zotano, AG
    Ariño, LP
    Saera, JM
    Abad, LP
    Lorenzo, JP
    Ortiz, AG
    Beveridge, RD
    Huerta, AS
    Salcedo, JM
    LUNG CANCER, 2005, 49 : S246 - S246
12345